COX Share Price

Open 11.76 Change Price %
High 11.88 1 Day 0.07 0.60
Low 11.65 1 Week 0.21 1.81
Close 11.81 1 Month 0.31 2.70
Volume 64981 1 Year 0.24 2.07
52 Week High 13.68
52 Week Low 7.05
COX Important Levels
Resistance 2 12.02
Resistance 1 11.94
Pivot 11.78
Support 1 11.68
Support 2 11.60
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
MLSTR 15.51 44.68%
APAM 33.78 15.72%
APAM 33.78 15.72%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
MLATV 2.60 -46.72%
MLFCI 0.16 -36.00%
MLACP 1.81 -26.72%
MLSBT 5.62 -9.21%
SEC 0.87 -8.42%
SEC 0.87 -8.42%
ECP 3.53 -8.31%
ECP 3.53 -8.31%
ECP 3.53 -8.31%
HBW 0.16 -5.88%
More..

Nicox (EPA: COX)

COX Technical Analysis 4
As on 24th Jul 2017 COX Share Price closed @ 11.81 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 9.35 & Buy for SHORT-TERM with Stoploss of 11.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
COX Target for July
1st Target up-side 13.08
2nd Target up-side 13.92
3rd Target up-side 14.76
1st Target down-side 10.7
2nd Target down-side 9.86
3rd Target down-side 9.02
COX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.nicox.com
COX Address
COX
Drakkar 2 - B
2405 route des Dolines
Sophia Antipolis, 06906
France
Phone: 33 4 97 24 53 00
Fax: 33 4 97 24 53 99
COX Latest News
Nicox SA (COX&KINGS.NS) Shares Moving On Volume   Evergreen Caller   - 20th Jul 17
Zacks: NICOX SA EUR1 (NASDAQ:NICXF) Given Average Recommendation of “Hold” by ...   BNB Daily (blog)   - 20th Jul 17
Nicox: Issuing and admission to trading on the Euronext regulated market in ...   GlobeNewswire (press release)   - 08th Jun 17
Nicox Eyes Partner After First Approval   Seeking Alpha   - 05th Jun 17
Nicox resubmits AC-170 NDA after API supplier resolves GMP issues   In-PharmaTechnologist.com   - 09th Mar 17
Why Nicox (NICXF) Could Be a Potential Winner August 01, 2016   Zacks.com   - 01st Aug 16
Nicox to transfer Commercial Operations to new pan-European Ophthalmic ...   GlobeNewswire (press release)   - 05th Jul 16
US FDA Grants Priority Review For Nicox's AC-170 New Drug Application   Clinical Leader   - 22nd Jun 16
Nicox and Fera Pharmaceuticals sign exclusive license agreement for ...   GlobeNewswire (press release)   - 10th Nov 15
Nicox to acquire Aciex Therapeutics, Inc.   GlobeNewswire (press release)   - 02nd Jul 14
Interactive Technical Analysis Chart Nicox ( COX EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Nicox
COX Business Profile
NicOx S.A. develops a portfolio of therapies and diagnostic tools to enhance sight in the United States, Europe, and internationally. It provides AdenoPlus a diagnostic test that offers eyecare professionals to diagnose and manage patients with an acute red eye. The company’s pipeline product, Latanoprostene bunod, is in Phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it is engaged in the research and development of nitric oxide steroids for the treatment of back and front of the eye disease; and NO-donors for eye disorder applications. Further, the company develops Naproxcinod, an anti-inflammatory candidate that is in regulatory review with the US Food and Drug Administration for the treatment of signs and symptoms of osteoarthritis; nitric oxide for cardiovascular indications; and NCX 1047, a dermatology anti-inflammatory drug-candidate, which is in preclinical stage of development. NicOx S.A. has collaboration with Bausch + Lomb, Merck, and Grupo Ferrer Internacional S.A. The company was founded in 1996 and is headquartered in Sophia Antipolis, France.